About this Journal Submit a Manuscript Table of Contents
ISRN Urology
Volume 2012 (2012), Article ID 748235, 8 pages
http://dx.doi.org/10.5402/2012/748235
Review Article

Renal Cell Carcinoma Update: News from the AUA, EAU, and ASCO Annual Meetings 2011

1Department of Urology, Ulm University Medical Center, Prittwitzstrasse 43, 89075 Ulm, Germany
2Department of Urology, Hannover University Medical School (MHH), 30625 Hanover, Germany

Received 21 January 2012; Accepted 4 March 2012

Academic Editors: B. Delahunt, J. H. Ku, and T. Takayama

Copyright © 2012 Andres Jan Schrader and Sandra Steffens. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. GEKID: Cancer in Germany—Incidence and Trends, vol. 6: Robert Koch Institute, pp. 78–81, 2008, http://www.gekid.de.
  2. S. Bundesamt, Sterblichkeit, Todesursachen und reginonale Unterschiede: Todesursachenstatistik, 2008.
  3. K. Nepple and S. Strope, “Population-based analysis of the rising incidence of renal cancer: evaluation of age-specific trands,” Journal of Urology, vol. 185, no. 4, Article ID e387, 2011.
  4. M. Tsivian, M. Ferrandino, V. Mouraviev, M. Kimura, D. Albala, and T. Polascik, “Small renal masses: should current treatment strategy be reappraised ?” Journal of Urology, vol. 185, no. 4, pp. e502–e503, 2011.
  5. I. Frank, M. L. Blute, J. C. Cheville, C. M. Lohse, A. L. Weaver, and H. Zincke, “Solid renal tumors: an analysis of pathological features related to tumor size,” Journal of Urology, vol. 170, no. 6, pp. 2217–2220, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Smaldone, A. Kutikov, B. Egleston et al., “Characteristics of small renal masses progressing to metastases while under observation: a pooled analysis,” Journal of Urology, vol. 185, no. 4, abstract 1663, Article ID e668, 2011.
  7. M. M. Nguyen and I. S. Gill, “Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality,” Journal of Urology, vol. 181, no. 3, pp. 1020–1027, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. J.-S. Chang, Y. H. Park, J. H. Ku et al., “Predicting factors for other cause related death in patients with localized renal cell carcinoma,” Journal of Urology, vol. 185, no. 4, abstract 1270, Article ID e508.
  9. B. Ljungberg, N. C. Cowan, D. C. Hanbury et al., “EAU guidelines on renal cell carcinoma: the 2010 update,” European Urology, vol. 58, no. 3, pp. 398–406, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Gudmundsson, H. Hellborg, S. Lundstam, S. Erikson, and B. Ljungberg, “Metastatic potential in renal cell carcinomas ≤7 cm: Swedish kidney cancer quality register data,” European Urology, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. A. S. Jewett, K. Mattar, J. Basiuk et al., “Active surveillance of small renal masses: progression patterns of early stage kidney cancer,” European Urology, vol. 60, no. 1, pp. 39–44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. S. N. Chawla, P. L. Crispen, A. L. Hanlon, R. E. Greenberg, D. Y. T. Chen, and R. G. Uzzo, “The natural history of observed enhancing renal masses: meta-analysis and review of the world literature,” Journal of Urology, vol. 175, no. 2, pp. 425–431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. M. Deshmukh, L. Sequeira, F. McGovern et al., “Percutaneous biopsy of suspicious cystic renal masses: what is the diagnostic yield?” Journal of Urology, vol. 185, no. 4, abstract 701, Article ID e282, 2011.
  14. S. M. Deshmukh, L. Sequeira, F. McGovern et al., “Percutaneous renal mass biopsy: if they are postive, they are positive, but if they are negative, be careful ! A correlation between renal biopsy and surgical pathology,” Journal of Urology, vol. 185, no. 4, abstract 704, Article ID e283, 2011.
  15. D. Londono, M. Wuerstle, T. Danial, and G. Chien, “Accuracy and implication of percutaneous renal biopsy in the management of renal masses,” Journal of Urology, vol. 185, no. 4, pp. e279–e280, 2011.
  16. J. M. Woldrich, S. Stroup, K. Palazzi-Churas, R. L. Sur, D. Chang, and I. H. Derweesh, “Surgical management of renal lesions in the nationwide inpatient sample,” Journal of Urology, vol. 185, no. 4, pp. e435–e436, 2011.
  17. M. Kates, G. M. Badalato, N. Sadeghi, M. S. Pitman, and J. M. McKiernan, “Increased risk of overall and cardiovascular mortality after radical nephrectomy for renal cell carcinoma less than or equal to 2 cm,” Journal of Clinical Oncology, vol. 29, supplement 15, abstract 4589, 2011.
  18. A. Antonelli, G. Novara, C. Simeone et al., et al., “Partial and radical nephrectomy for pT1 renal cell carcinoma: results of the SATURN project,” Journal of Urology, vol. 185, no. 4, abstract 1762, Article ID e707, 2011.
  19. M. Childs, C. Lohse, J. Cheville et al., “Radical nephrectomy for benign renal masses is associated with diminished overall survival compared with partial nephrectomy,” Journal of Urology, vol. 185, no. 4, abstract 1073, Article ID e431, 2011.
  20. S. L. Chang, L. E. Cipriano, S. M. Brunelli, and B. I. Chung, “Economic and clinical consequences of new onset post-operative chronic kidney disease following radical and partial nephrectomy in the management of small renal masses,” Journal of Urology, vol. 185, no. 4, pp. e612–e613, 2011.
  21. M. Sun, C. Jeldres, R. Thuret et al., “Complications of the laparoscopic vs. the open techniques in patients with non-metastatic renal cell carcinoma (RCC) treated with partial or radical nephrectomy: a population-based analysis of the United States,” European Urology Supplements, vol. 10, no. 2, abstract 194, 2011.
  22. J.-R. Hoff, R. E. Berg, N. Wessel, and V. Berge, “Laparoscopic partial nephrectomy versus robot assisted partial nephrectomy for renal tumors: a single -institutional analysis of perioperative outcomes,” European Urology Supplements, vol. 10, no. 2, abstract 187, 2011.
  23. T. J. Schnoeller, R. de Petriconi, R. Hefty et al., “Partial nephrectomy using porcine small intestinal submucosa,” World Journal of Surgical Oncology, vol. 9, no. 126, pp. 1–5, 2011.
  24. J. Whitson, C. Harris, and M. Meng, “Comparative effectiveness of partial nephrectomy versus ablation of small renal masses in a population based cohort,” Journal of Urology, vol. 185, no. 4, abstract 1531, Article ID e615, 2011.
  25. M. Brausi, G. L. Giliberto, G. De Luca et al., “Mininvasive open tumor enucleation (TE) vs. percutaneous radiofrequency ablation (PRA) vs. active surveillance (AS) of small renal masses < 3 cm in old patients: long term results of a prospective follow-up study,” European Urology Supplements, vol. 10, no. 2, abstract 290, 2011.
  26. T. Klatte, B. Grubmüller, M. Waldert, P. Weibl, and M. Remzi, “Laparoscopic cryoablation versus partial nephrectomy for the treatment of small renal masses: systematic review and cumulative analysis of observational studies,” European Urology, vol. 60, no. 3, pp. 435–443, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Psutka, A. Daha, F. McGovern et al., “Radiofrequency ablation of centrally located renal tumors is associated with increased rates of Clavien grade 3/4 complications,” Journal of Urology, vol. 185, no. 4, abstract 1266, Article ID e506, 2011.
  28. J. Du, J. Zheng, P. Peng, and X. Yao, “High preoperative plasma fibrinogen is an independent predictor of distant metastasis and poor prognosis on renal cell carcinoma,” Journal of Urology, vol. 185, no. 4, pp. e386–e387, 2011.
  29. T. Johnson, W. Harris, A. Abbasi et al., “CRP-based classification of localized renal cell carcinoma patients into low, intermediate, and high risk of mortality,” Journal of Urology, vol. 185, no. 4, abstract 1660, Article ID e667, 2011.
  30. T. Johnson, V. Master, A. Abbasi et al., “Intratumoral C-reactive protein as a biomarker of prognosis in localized renal cell carcinoma,” Journal of Urology, vol. 185, no. 4, pp. e667–e668, 2011.
  31. C. Valotto, G. Novara, A. Antonelli et al., “Prognostic role of tumor necrosis in clear cell renal cell carcinoma: results of the SATURN project,” Journal of Urology, vol. 185, no. 4, abstract 1999, Article ID e800, 2011.
  32. V. Margulis, R. Youssef, P. Kapur et al., “The number of aberrantly expressed constituents of the mammalian target of rapamycin pathway: correlation with oncologic outcomes in clear cell renal cell carcinoma,” Journal of Urology, vol. 185, no. 4, abstract 1081, Article ID e435, 2011.
  33. M. Hussain, R. Nair, J. Bycroft, J. Green, T. Powles, and J. L. Peters, “A comparison of open radical nephrectomy complication rates in patients treated with neoadjuvant sunitinib for metastatic renal cell carcinoma versus non-metastatic renal cell carcinoma,” European Urology Supplements, vol. 10, no. 2, abstract 262, 2011.
  34. M. Crepel, P. Bigot, J.-C. Bernhard et al., “Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favourable MSKCC or ECOG prognostic features,” European Urology Supplements, vol. 10, no. 2, abstract 256, 2011.
  35. M. Nozawa, N. Matsumura, M. Yasuda, Y. Okuda, and H. Uemura, “Difference of response to targeted therapy between the primary tumor and metastatic lesions in patients with advanced renal cell carcinoma,” European Urology Supplements, vol. 10, no. 2, abstract 726, 2011.
  36. B. Melichar, S. Bracarda, V. Matveev et al., et al., “BEVLiN: prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC),” Journal of Clinical Oncology, vol. 29, supplement 15, abstract 4546, 2011.
  37. J. Busch, C. Kempkensteffen, V. Gruenwald et al., “Sequential use of mTOR-inhibitors in patients with metastatic renal cell carcinoma (mRCC): safety and efficacy following failure of receptor tyrosine kinase inhibitor (TKI) treatment,” European Urology Supplements, vol. 10, no. 2, abstract 725, 2011.
  38. B. I. Rini, B. Escudier, P. Tomczak et al., “Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial,” Journal of Clinical Oncology, vol. 29, supplement 15, abstract 4503, 2011.
  39. J. A. Reeves, D. R. Spigel, D. B. Daniel, E. K. Friedman, H. A. Burris, and J. D. Hainsworth, “Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab: a Sarah Cannon Research Institute phase II trial,” Journal of Clinical Oncology, vol. 29, supplement 15, abstract 4659, 2011.
  40. S. Kapadia, S. Hapani, and S. Wu, “Risk of high-grade liver toxicity with pazopanib in patients with cancer: a meta-analysis,” Journal of Clinical Oncology, vol. 29, supplement 15, abstract 4595, 2011.